Legend Biotech (LEGN) Change in Accured Expenses (2020 - 2026)

Legend Biotech (LEGN) has 7 years of Change in Accured Expenses data on file, last reported at -$65.2 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 66.75% year-over-year to -$65.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$76.2 million (down 9570.81% YoY) and the FY2024 annual result came in at $45.7 million, up 3587.94% from the prior year.
• Change in Accured Expenses eased to -$65.2 million in Q1 2026, from $6.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $75.9 million in Q2 2022 to a low of -$65.2 million in Q1 2026.
• A 5-year average of $5.5 million and a median of $4.2 million in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses jumped 1476.25% — and 2025, when it slumped 629.81%.
• Tracing LEGN's Change in Accured Expenses over 5 years: stood at $1.7 million in 2022, then jumped by 1476.25% to $27.5 million in 2023, then plunged by 105.36% to -$1.5 million in 2024, then surged by 558.97% to $6.8 million in 2025, then plunged by 1065.07% to -$65.2 million in 2026.
• The last three Change in Accured Expenses figures came in at -$65.2 million (Q1 2026), $6.8 million (Q3 2025), and $21.3 million (Q2 2025), per Business Quant data.